Oxford Immunotec sought a preliminary injunction to prevent the sale of the Qiagen product to new customers in the US.
The Ultra's combination of a lower limit of detection and ability to find dead bacilli after starting TB therapy vastly improves sensitivity compared to other tests, the study’s authors said.
The study is the first to demonstrate the design features and operational characteristics of Cepheid's Xpert MTB/RIF Ultra assay.
The company's year over year revenue growth was driven by continued growth in both its tuberculosis and tick-borne disease testing franchises.
The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
A UK-led international consortium is sequencing tuberculosis genomes and cataloguing drug resistance mutations to enable more rapid NGS-based diagnostics.
Among the tests that French national health insurance system will reimburse are IGRA tests, including ones from Qiagen and Oxford Immunotec, for screening TB.